Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump

MT Newswires Live

Dec 14, 2024

Bicycle Therapeutics (BCYC) shares fell more than 31% in recent Friday trading after the company said topline data from a phase 1/2 trial of zelenectide pevedotin combined with Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.

The company said it plans to report dose selection and topline data from a phase 2/3 trial in H2 2025.

Bicycle also said treatment with zelenectide pevedotin alone in breast cancer patients with Nectin4 gene amplification showed "enhanced anti-tumor activity."

The company said it will advance its development strategy, including phase 1/2 trials in breast, lung, and multi-tumor cancers, starting in 2025.

Price: 13.77, Change: -6.35, Percent Change: -31.55

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491301013"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491301013\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491301013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 02:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491301013","market":"hk","top_or_hot":-1,"title":"Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump","media":"MT Newswires Live","content":"<html><body><p> Bicycle <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCYC) shares fell more than 31% in recent Friday trading after the company said topline data from a phase 1/2 trial of zelenectide pevedotin combined with Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.</p><p>The company said it plans to report dose selection and topline data from a phase 2/3 trial in H2 2025.</p><p>Bicycle also said treatment with zelenectide pevedotin alone in breast cancer patients with Nectin4 gene amplification showed \"enhanced anti-tumor activity.\"</p><p>The company said it will advance its development strategy, including phase 1/2 trials in breast, lung, and multi-tumor cancers, starting in 2025.</p><p>Price: 13.77, Change: -6.35, Percent Change: -31.55</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-14 02:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bicycle <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCYC) shares fell more than 31% in recent Friday trading after the company said topline data from a phase 1/2 trial of zelenectide pevedotin combined with Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.</p><p>The company said it plans to report dose selection and topline data from a phase 2/3 trial in H2 2025.</p><p>Bicycle also said treatment with zelenectide pevedotin alone in breast cancer patients with Nectin4 gene amplification showed \"enhanced anti-tumor activity.\"</p><p>The company said it will advance its development strategy, including phase 1/2 trials in breast, lung, and multi-tumor cancers, starting in 2025.</p><p>Price: 13.77, Change: -6.35, Percent Change: -31.55</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2491301013","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491301013","pubTimestamp":1734115981,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bicycle Therapeutics  shares fell more than 31% in recent Friday trading after the company said topline data from a phase 1/2 trial of zelenectide pevedotin combined with Merck's  pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.The company said it plans to report dose selection and topline data from a phase 2/3 trial in H2 2025.Bicycle also said treatment with zelenectide pevedotin alone in breast cancer patients with Nectin4 gene amplification showed \"enhanced anti-tumor activity.\"The company said it will advance its development strategy, including phase 1/2 trials in breast, lung, and multi-tumor cancers, starting in 2025.Price: 13.77, Change: -6.35, Percent Change: -31.55","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4007":"制药","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0058720904.USD":"联博国际健康护理基金A","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","MRK":"默沙东","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","BK4585":"ETF&股票定投概念","BCYC":"Bicycle Therapeutics Limited","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4516":"特朗普概念","LENZ":"Therapeutics","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC"},"translate_title":"Bicycle Therapeutics报告了Zelenectide Pevedotin计划的更新；股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9,"BCYC":0.9,"LENZ":1},"content_text":"Bicycle Therapeutics (BCYC) shares fell more than 31% in recent Friday trading after the company said topline data from a phase 1/2 trial of zelenectide pevedotin combined with Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.The company said it plans to report dose selection and topline data from a phase 2/3 trial in H2 2025.Bicycle also said treatment with zelenectide pevedotin alone in breast cancer patients with Nectin4 gene amplification showed \"enhanced anti-tumor activity.\"The company said it will advance its development strategy, including phase 1/2 trials in breast, lung, and multi-tumor cancers, starting in 2025.Price: 13.77, Change: -6.35, Percent Change: -31.55","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}